GenVec abandoned a clinical trial of TNFerade after preliminary results showed that the gene therapy reduced the risk of death by about 8% when combined with chemotherapy and radiation in patients with advanced pancreatic cancer compared to standard therapy alone. The biotech firm intends to conduct further analysis of the drug and monitor study participants.

Full Story:

Related Summaries